US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

As a herding dog breed, Australian Cattle Dogs have very high energy levels and they need as much exercise as you can give ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

This marks the first approved treatment for ... It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision.

IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...

Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...

SYFOVRE is the first and only approved treatment for ... 1 It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision.

SYFOVRE is the first and only approved treatment for GA in Australia ... cause of blindness worldwide. 1 It is a progressive and irreversible disease caused by the growth of lesions, which destroy the ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...